ACMR vs DBD

ACMR's Piotroski F-Score of 2/9 indicates severe financial distress, with weak operational and profitability health. The Altman Z-Score is unavailable, but the company's negative earnings growth (-77.7% YoY) and declining EPS trend signal deteriorating fundamentals. Despite a strong gross margin (44.39%) and low debt/equity (0.15), the sharp drop in earnings and poor recent earnings surprises (average -20.81% over last 4 quarters) undermine confidence. The stock trades at a premium to its Graham Number ($26.23) and intrinsic value ($9.59), suggesting overvaluation relative to conservative metrics. Insider selling of $16.59M in the last 6 months further reinforces bearish sentiment.

DBD presents a stark dichotomy between explosive earnings growth and concerning sentiment indicators. With a Piotroski F-Score of 4/9, the company's financial health is categorized as stable but lacks strong momentum. While the stock currently trades at a premium to its Graham Number ($42.15) and Intrinsic Value ($74.93), the low forward P/E of 12.75 suggests the market is pricing in continued earnings acceleration. However, heavy insider liquidation and a bearish technical trend significantly offset the strong analyst 'strong_buy' consensus.